you know there is a decent chance that ofatumumab will take a good chunk of cll and NHL pts, even if no benefit is seen over rituxan. i don't see this gaining much market share in RA. The PPMS market is small and may be a longshot. the only hope of continued growth in this franchise is lupus IMHO. this could be a falling franchise in a year or two
Market Data 
Markets 
AI
